Kari Wisinski, Professor, Chief of Hematology, Medical Oncology and Palliative Care
Dr. Kari Wisinski is the Division Chief of Hematology, Medical Oncology and Palliative Care at the University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center.
Dr. Wisinski is a breast cancer expert. Her research focuses on developing and testing new treatments for breast cancer, especially metastatic disease. Dr. Wisinski has led multiple trials through national and regional research networks. At the UW Carbone Cancer Center, she is the co-leader of the Breast Cancer Disease-Oriented Team and the Associate Director for Clinical Research. Nationally, she has led the Big Ten Cancer Research Consortium Breast Cancer Working Group and is a prior chair and current member of the BTCRC Steering Committee. She is the deputy editor of Clinical Breast Cancer and a member of the National Comprehensive Cancer Network (NCCN) Steering Committee and Breast Cancer Guidelines panel.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:PfizerTopic:IIT support through BTCRCDate added:05/29/2024Date updated:05/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:PfizerTopic:Advisory boardDate added:05/29/2024Date updated:05/29/2024Relationship end date:12/05/2022
-
Attribution:SelfType of financial relationship:OtherIneligible company:PfizerTopic:site PI for clinical trialDate added:05/29/2024Date updated:05/29/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:NovartisTopic:IIT supportDate added:05/29/2024Date updated:05/29/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:NovartisTopic:Site PI for clinical trialDate added:05/29/2024Date updated:05/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:StemlineTopic:Advisory boardDate added:05/29/2024Date updated:05/29/2024Relationship end date:05/30/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GileadTopic:Advisory BoardDate added:05/29/2024Date updated:05/29/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:SeagenTopic:Advisory boardDate added:05/29/2024Date updated:05/29/2024Relationship end date:01/24/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:LoxoLillyTopic:Advisory BoardDate added:05/29/2024Date updated:05/29/2024Relationship end date:09/21/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AstraZenecaTopic:Advisory BoardDate added:05/29/2024Date updated:05/29/2024Relationship end date:12/01/2023